[go: up one dir, main page]

WO2025024258A3 - Ebv status as a predictor of response to immunotherapy - Google Patents

Ebv status as a predictor of response to immunotherapy Download PDF

Info

Publication number
WO2025024258A3
WO2025024258A3 PCT/US2024/038706 US2024038706W WO2025024258A3 WO 2025024258 A3 WO2025024258 A3 WO 2025024258A3 US 2024038706 W US2024038706 W US 2024038706W WO 2025024258 A3 WO2025024258 A3 WO 2025024258A3
Authority
WO
WIPO (PCT)
Prior art keywords
predictor
immunotherapy
response
ebv
status
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/038706
Other languages
French (fr)
Other versions
WO2025024258A2 (en
Inventor
Meagan Kathleen MONTESION
Dexter X. JIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foundation Medicine Inc
Original Assignee
Foundation Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation Medicine Inc filed Critical Foundation Medicine Inc
Publication of WO2025024258A2 publication Critical patent/WO2025024258A2/en
Publication of WO2025024258A3 publication Critical patent/WO2025024258A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein are methods related to detection of Epstein-Barr virus (EBV) status as a predictor of human leukocyte antigen (HLA)-I loss-of-heterozygosity (LOH) and/or responses to treatment comprising an immunotherapy.
PCT/US2024/038706 2023-07-21 2024-07-19 Ebv status as a predictor of response to immunotherapy Pending WO2025024258A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363528227P 2023-07-21 2023-07-21
US63/528,227 2023-07-21

Publications (2)

Publication Number Publication Date
WO2025024258A2 WO2025024258A2 (en) 2025-01-30
WO2025024258A3 true WO2025024258A3 (en) 2025-04-10

Family

ID=94375137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/038706 Pending WO2025024258A2 (en) 2023-07-21 2024-07-19 Ebv status as a predictor of response to immunotherapy

Country Status (1)

Country Link
WO (1) WO2025024258A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190256924A1 (en) * 2017-08-07 2019-08-22 The Johns Hopkins University Methods and materials for assessing and treating cancer
WO2022272309A1 (en) * 2021-06-25 2022-12-29 Foundation Medicine, Inc. Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190256924A1 (en) * 2017-08-07 2019-08-22 The Johns Hopkins University Methods and materials for assessing and treating cancer
WO2022272309A1 (en) * 2021-06-25 2022-12-29 Foundation Medicine, Inc. Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Epstein-Barr Virus (EBV) Gene Expression in EBV-Positive Peripheral T- Cell Lymphomas", JOURNAL OF VIROLOGY, vol. 67, no. 10, October 1993 (1993-10-01), pages 6303 - 6308, XP000909597 *
LI JING-YI, CHEN XIAO-PING, TIE YAN-QING, SUN XIU-LI, ZHANG RUI-QING, HE AN-NA, NIE MING-ZHU, FAN GUO-HAO, LI FENG-YU, TIAN FENG-Y: "Detection of low-load Epstein-Barr virus in blood samples by enriched recombinase aided amplification assay", AMB EXPRESS, vol. 12, no. 1, 1 December 2022 (2022-12-01), DE , pages 1 - 8, XP093303804, ISSN: 2191-0855, DOI: 10.1186/s13568-022-01415-9 *
PANDA ANSHUMAN, MEHNERT JANICE M, HIRSHFIELD KIM M, RIEDLINGER GREG, DAMARE SHERRI, SAUNDERS TRACIE, KANE MICHAEL, SOKOL LEVI, STE: "Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 110, no. 3, 1 March 2018 (2018-03-01), GB , pages 316 - 320, XP093303798, ISSN: 0027-8874, DOI: 10.1093/jnci/djx213 *
SAMPLE J, YOUNG L, MARTIN B, CHATMAN T, KIEFF E, RICKINSON A, KIEFF E: "Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes", JOURNAL OF VIROLOGY, vol. 64, no. 9, 1 September 1990 (1990-09-01), US , pages 4084 - 4092, XP093303800, ISSN: 0022-538X, DOI: 10.1128/jvi.64.9.4084-4092.1990 *

Also Published As

Publication number Publication date
WO2025024258A2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
López et al. Treg-inducing membrane vesicles from Bifidobacterium bifidum LMG13195 as potential adjuvants in immunotherapy
Frasca et al. High TNF-α levels in resting B cells negatively correlate with their response
Mason et al. Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4+ T cells
Vieira et al. Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size
WO2025024258A3 (en) Ebv status as a predictor of response to immunotherapy
WO2022082014A3 (en) Skin targeted immunotolerance
Tovar-Salazar et al. Understanding the mechanism of action of cytomegalovirus-induced regulatory T cells
Caramalho et al. Bee venom enhances the differentiation of human regulatory T cells
Raïch-Regué et al. Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy
Fialová et al. Ixodes ricinus tick saliva modulates tick-borne encephalitis virus infection of dendritic cells
Dhanwani et al. Profiling human cytomegalovirus-specific T cell responses reveals novel immunogenic open reading frames
Sili et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
Naouar et al. Involvement of different CD4+ T cell subsets producing granzyme B in the immune response to Leishmania major antigens
Falcão et al. The presence of Tregs does not preclude immunity to reinfection with Leishmania braziliensis
Wang et al. Schistosoma japonicum HSP60-derived peptide SJMHE1 suppresses delayed-type hypersensitivity in a murine model
Lopes et al. Dendritic cell profile induced by Schistosoma mansoni antigen in cutaneous leishmaniasis patients
EP3931550A4 (en) TISSUE DETECTION SYSTEM AND METHODS OF USE
Picherot et al. Swine infection with Trichinella spiralis: Comparative analysis of the mucosal intestinal and systemic immune responses
Rezende-Oliveira et al. Analysis of regulatory T cells and CTLA-4 expression in pregnant women according to seropositivity to Toxoplasma gondii
CA3263295A1 (en) Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
Ma et al. A negative feedback loop between autophagy and immune responses in Mycobacterium leprae infection
Zhong et al. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases
Marios-Frankiskos et al. Serum-derived MHC class II molecules: potent regulators of the cellular and humoral immune response
Teixeira et al. Biological markers changes at the very early stage of ageing (60-65 years). Is there a gender-related effect?
EP4097485A4 (en) Methods of diagnosing and classifying viral infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24846257

Country of ref document: EP

Kind code of ref document: A2